GlassScriptPhysician profile
William B Bradley
NPI 1649375940
$4,042.25
in general payments reported to CMS, 2019-2025
30 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,012 · 2022: $589 · 2023: $730 · 2024: $562 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.13 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.71 | 2021-2025 | Breztri, Farxiga |
| Abbvie INC. | $497.74 | 2021-2025 | |
| Lilly USA, LLC | $446.05 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.46 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $308.77 | 2021-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $225.98 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $197.15 | 2022-2024 | |
| Novo Nordisk INC | $190.08 | 2021-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $152.88 | 2021-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $96.52 | 2021-2025 | |
| Boston Scientific Corporation | $91.77 | 2025 | Lumenis Pulse 120h |
| Kowa Pharmaceuticals America, INC. | $91.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $85.04 | 2022-2025 | Rexulti |
| Pfizer INC. | $54.79 | 2021-2025 | |
| Dexcom, INC. | $51.98 | 2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.84 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $43.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $43.09 | 2023 | Spravato |
| Abbott Laboratories | $38.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.45 | 2021 | |
| Seqirus USA INC | $33.98 | 2024 | Flucelvax, Fluad |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.43 | 2024 | Caplyta |
| Eisai INC. | $18.59 | 2021 | |
| Grifols USA, LLC | $17.96 | 2024 | Prolastin-C Liquid |
| Corcept Therapeutics | $16.69 | 2022 | |
| Medicomp INC | $16.14 | 2023 | Telepatch Cardiac Monitor |
| Ironwood Pharmaceuticals, INC | $15.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.30 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.